September 10-12, Wuxi · 2024 The 3rd Global Innovation Summit on Bio-Conjugate Drugs is about to convene! Nearly a hundred international life science experts gather to explore the limitless possibilities of conjugate drugs!
On August 20, 2024, Puzhong Discovery and ADCendo jointly announced that they have reached a licensing agreement for a novel, highly differentiated antibody-drug conjugate (ADC) targeting tissue factor (Anti-TF), codenamed ADCE-T02 (Puzhong Discovery's research and development code: AMT-754). ADCendo will obtain exclusive global development and commercialization rights outside of Greater China, while Puzhong Discovery will retain the development and commercialization rights in Greater China (including mainland China, the Hong Kong Special Administrative Region, the Macao Special Administrative Region, and Taiwan region).
According to the financial terms of the agreement, Puzhong Discovery will receive a prepayment of tens of millions of US dollars and additional payments upon achieving subsequent development, regulatory, and commercial milestones.Will receive total milestone payments exceeding 1 billion US dollars, and a single-digit to low double-digit percentage royalty on net sales worldwide (excluding Greater China).Tissue Factor (TF) is overexpressed in bladder cancer, non-small cell lung cancer, colorectal cancer, cervical cancer, esophageal cancer, head and neck cancer, and gastrointestinal cancer, but its expression is restricted in normal tissues, making it an excellent ADC target.ADCE-T02 is a novel, highly differentiated Anti-TF ADC. Its unique antibody design can reduce the impact on the coagulation pathway. Meanwhile, the T1000-exatecan linker-payload technology platform has been proven to amplify the "bystander effect," enhance linker stability, and possess the potential to overcome resistance mechanisms. These differentiated characteristics are expected to translate into higher clinical response rates, longer duration of efficacy, and better safety, offering a superior therapeutic window.ADCE-T02 has been submitted for clinical trial in Australia and is expected to file for U.S. IND soon.Puzhong Discovery Pharmaceutical Technology(Shanghai) Co., Ltd."We are delighted to launch a global collaboration with Adcendo. ADCE-T02 utilizes the T1000-exatecan linker-payload platform, and this successful partnership signifies the platform’s significant contribution across multiple successful ADC pipelines. We look forward to Adcendo's experienced global development and clinical teams bringing ADCE-T02 to cancer patients in need as soon as possible."ADCendo stated"We are impressed by the scientific research on the T1000-exatecan linker-payload platform and are delighted with the licensing agreement we have reached for ADCE-T02. This collaboration perfectly complements our existing first-in-class ADC pipeline. As showcased at the recent annual ASCO conference, TF is an excellent ADC target with tremendous potential in a wide range of indications with significant unmet needs. The highly differentiated design of ADCE-T02 can fully leverage the advantages of this target, with the potential to bring real benefits to more cancer patients."Source of the article: Puzhong Discovery
The 3rd Global Innovation Summit on Biologics Conjugate Drugs (Global XDC 2024), jointly hosted by WuXi XDC and BioValley, will be held onSeptember 10-12Returns Heavily in Wuxi. The Conference Covers 2 Main Forums + 4 Sub-Forums, with an Estimated Participation of Companies300+Family, Participating Experts100+ Participants, Attendees1000+ peopleThe conference, themed "Exploring the Infinite Possibilities of Conjugated Drugs," will focus on new target discovery and validation, innovative ADC and novel conjugated drug technologies, payload-linker advancements, as well as CMC challenges and commercialization strategies.Explore cutting-edge technological advancements, share innovative experiences from outstanding international biotech companies, and lead the new future of ADC and XDC!
This summit invites numerous international experts in the field of bioconjugate drugs to participate, jointly explore innovative collaborations, exchange ideas, and promote the vigorous development of the bioconjugate drug industry.
↓↓↓ Click "Read Original" to explore the infinite possibilities of conjugated drugs.
